- Home
- IBCP vs GHRS Comparison
IBCP vs GHRS Comparison
Compare IBCP & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBCP
- GHRS
- Stock Information
- Founded
- IBCP 1864
- GHRS 2018
- Country
- IBCP United States
- GHRS Ireland
- Employees
- IBCP N/A
- GHRS N/A
- Industry
- IBCP Major Banks
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- IBCP Finance
- GHRS Health Care
- Exchange
- IBCP Nasdaq
- GHRS Nasdaq
- Market Cap
- IBCP 664.3M
- GHRS 583.1M
- IPO Year
- IBCP N/A
- GHRS 2021
- Fundamental
- Price
- IBCP $31.22
- GHRS $11.56
- Analyst Decision
- IBCP Hold
- GHRS Strong Buy
- Analyst Count
- IBCP 3
- GHRS 8
- Target Price
- IBCP $36.67
- GHRS $30.63
- AVG Volume (30 Days)
- IBCP 71.1K
- GHRS 151.6K
- Earning Date
- IBCP 07-24-2025
- GHRS 05-08-2025
- Dividend Yield
- IBCP 3.32%
- GHRS N/A
- EPS Growth
- IBCP 6.78
- GHRS N/A
- EPS
- IBCP 3.14
- GHRS N/A
- Revenue
- IBCP $219,516,000.00
- GHRS N/A
- Revenue This Year
- IBCP N/A
- GHRS N/A
- Revenue Next Year
- IBCP $6.04
- GHRS N/A
- P/E Ratio
- IBCP $10.04
- GHRS N/A
- Revenue Growth
- IBCP 6.57
- GHRS N/A
- 52 Week Low
- IBCP $22.53
- GHRS $6.00
- 52 Week High
- IBCP $40.32
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- IBCP 46.49
- GHRS 54.30
- Support Level
- IBCP $31.01
- GHRS $10.66
- Resistance Level
- IBCP $32.06
- GHRS $13.00
- Average True Range (ATR)
- IBCP 0.55
- GHRS 0.98
- MACD
- IBCP -0.13
- GHRS 0.06
- Stochastic Oscillator
- IBCP 11.67
- GHRS 55.46
About IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.